Michelle Miller

TL;DR: Among patients receiving initial systemic treatment for HR-positive, HER2-negative advanced breast cancer, the duration of progression-free survival was significantly longer among those receiving ribociclib plus letrozole than among those received placebo plus let rozole, with a higher rate of myelosuppression in the ribocIClib group.

TL;DR: Ribociclib plus fulvestrant might represent a new first- or second-line treatment option in hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer.

TL;DR: Improved efficacy outcomes and manageable tolerability observed with first-line ribociclib plus letrozole monotherapy are maintained with longer follow-up, relative to letrozo monotherapy.

TL;DR: It is shown that FGFR1 amplification is a resistance mechanism to CDK4/6 inhibitor and endocrine therapy and that combined treatment with FGFR, CDK 4/6, and anti-estrogens is a potential therapeutic strategy in Era+ breast cancer tumors.

TL;DR: Results indicate ribociclib plus letrozole may reduce Ki67 expression in HR+, HER2- BC and suggest absence of a drug-drug interaction between ribciclib and letroZole is suggested.